查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年製药器材组合产品的市场预测：按产品、用途、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1372023

到 2030 年製药器材组合产品的市场预测：按产品、用途、最终用户和地区进行的全球分析

Drug Device Combination Products Market Forecasts to 2030 - Global Analysis By Product, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球药物器材组合产品市场规模为 1,417 亿美元，预计到 2030 年将达到 2,924 亿美元，预测期内年复合成长率为 10.9%。

药物与医疗设备组合产品是指透过化学或物理性手段将医疗设备与药物活性物质结合形成「单一实体」的医疗设备。透过精准给药、局部给药和客製化治疗，这些解决方案有助于更安全、更有效率地管理和治疗多种疾病。例子包括药物洗脱支架、输液帮浦、吸入器、经皮给药系统、预充填式註射器和其他流行的药物设备组合产品。

根据 IDF 2021 的数据，大约有 5.37 亿成年人患有糖尿病，预计到 2030 年这一数字将增至 6.43 亿，到 2045 年将增至 7.83 亿。

产品发布数量增加

由于糖尿病、癌症、慢性呼吸系统疾病和心血管疾病等慢性病的患病不断增加，药械组合产品的市场正在不断扩大。例如，穿戴式生物感测器技术的顶级创新者Valencell计划于2023年1月推出。 Valencell 专门为各种用途提供准确可靠的生理监测。 Valensel 专注于将慢性病管理解决方案推向市场，宣布计划在数位健康产业开发自有品牌产品线。

製造挑战

组合药物和医疗设备产品可能具有复杂的製造程序，需要特定的设备和专业知识。製药和医疗设备整合通常需要复杂的组装、品管和无菌包装要求。然而，遵守良好生产规范 (GMP) 和品质要求可能很困难，从而导致製造成本增加和供应链问题。

政府配合措施

世界各国政府正在实施各种计划，以解决日益增加的慢性病负担并提高病人安全。这些活动非常重要，因此，药品和医疗设备组合产品的全球市场正在扩大。例如，2021 年 9 月，美国FDA 意识到人工智慧和机器学习在药物开发中的重大影响。今年，结构要素人工智慧/机器学习的药品和生物製药申请超过100件。人工智慧和机器学习应用于药物开发的各个阶段，包括药物研发发现、临床研究、安全监测和製造。

法规障碍

药物和医疗设备的组合产品需要遵守复杂的法规标准。获得法规许可并确保遵守各种法规机构（包括欧洲药品管理局 (EMA) 和美国食品药物管理局(FDA)）可能既耗时又昂贵。然而，在产品开发、临床试验和市场进入方面，製造商可能面临严格法规和不断变化的标准所带来的挑战。

COVID-19 的影响：

自2019年12月Covid-19病毒爆发以来，该疾病已传播到100多个国家，并于2020年1月30日被世界卫生组织（WHO）宣布为突发公共卫生事件。然而，全球药物器械组合产品市场受到了 COVID-19 疫情的严重影响。对呼吸设备的需求不断增长以及药物设备组合的技术创新正在塑造市场。然而，资源优先顺序、製造和供应链中断等问题正在出现。疫情激发了产业创新与合作，但长期影响尚待观察。

经皮贴片领域预计将成为预测期内最大的市场

由于需要长期治疗的疾病对自我给药药物的需求不断增加，预计经皮吸收贴片细分市场在预测期内将成长最高。例如，糖尿病患者需要频繁静脉注射胰岛素。此外，与频繁使用针头给药胰岛素相关的疼痛和感染风险增加增加了对替代药物传递方法的需求。

预计癌症治疗领域在预测期内的年复合成长率最高。

预计癌症治疗领域在预测期内的年复合成长率最高。这些产品透过整合药理物质和医疗设备来提高治疗效果，提供了一种独特的癌症治疗方法。它可以使用植入式药物传输装置、局部放射线治疗和标靶药物传输。此外，结合不同的治疗方法，包括化疗、免疫疗法和标靶治疗，可以提供协同效应和个体化的治疗选择。

占比最大的地区：

由于人口众多、癌症等慢性病发病率上升以及医疗保健成本上升，预计亚太地区在预测期内将占据最大的市场份额。此外，该地区的市场还受益于这些产品的优势，例如较低的剂量给药、药物的定时释放、与抗感染药物联合使用直接基于设备的感染缓解以及减少的全身暴露。这是医生对其益处的认识不断提高的结果。

复合年复合成长率最高的地区：

由于药物设备组合产品的采用以及该地区成熟的医疗基础设施，预计北美在预测期内将实现盈利增长。此外，由于许多疫苗和其他治疗方法都源自于这些行业，随着公司在产品研发上投入更多资金，对组合药物和医疗设备产品的需求可能会成长，而且很高。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球医药复方产品市场：副产品

  • 点滴帮浦
    • 胰岛素
    • 可嵌入的
    • 注射器
    • 门诊
  • 整形外科组合产品
    • 抗生素骨水泥
    • 骨移植植入物
  • 经皮吸收贴片
  • 动态治疗仪
  • 药物释放型支架
  • 创伤护理产品
  • 抗菌导管
    • 心血管
    • 泌尿系统
  • 其他产品

第6章全球医药复合产品市场：依用途

  • 糖尿病
  • 癌症治疗
  • 呼吸系统的问题
  • 其他用途

第7章全球医药复合产品市场：依最终用户分类

  • 家庭护理设置
  • 门诊手术中心
  • 医院和诊所
  • 其他最终用户

第8章全球医药复方产品市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第9章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第10章公司简介

  • Abbott Laboratories
  • Allergan plc
  • Boston Scientific Corporation
  • CR Bard
  • Medtronic Plc
  • Mylan NV
  • Novartis AG
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: SMRC24079

According to Stratistics MRC, the Global Drug Device Combination Products Market is accounted for $141.7 billion in 2023 and is expected to reach $292.4 billion by 2030 growing at a CAGR of 10.9% during the forecast period. Drug-device combination products are medical devices that combine a device and active medicinal substances to form a "single entity" by chemical or physical means. Due to precise medication delivery, local administration, and customized treatment, these solutions contribute to the safer, more efficient management and treatment of a number of illnesses. Drug-eluting stents, infusion pumps, inhalers, transdermal delivery systems, prefilled syringes, and other popular drug-device combo products are instances.

According to the IDF 2021, approximately 537 million adults are living with diabetes, and the number of people adults living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045.

Market Dynamics:

Driver:

A rise in product launches

The market for drug-device combination products is expanding due to the increased prevalence of chronic diseases such as diabetes, cancer, chronic respiratory diseases, and cardiovascular diseases. For instance, Valencell, a top innovator in wearable biometric sensor technology, will be available in January 2023. Valencell specializes in accurate and dependable physiological monitoring for a variety of applications. In order to concentrate its efforts on bringing solutions to market to manage chronic conditions, Valencell has announced plans to develop its own branded product line in the digital health industry.

Restraint:

Manufacturing challenges

Drug device combination products might have complicated manufacturing procedures that require specific equipment and expertise. Complex assembly, quality control, and sterile packaging requirements are frequently required for the integration of pharmaceuticals and devices. However, it can be challenging to adhere to good manufacturing practices (GMP) and quality requirements, which can raise production costs and cause supply chain issues.

Opportunity:

Governmental initiatives

Various programs are being implemented by governments all over the world to address the growing burden of chronic diseases and advance patient safety. The global market for drug device combination products is expanding as a result of these activities, which are extremely important. For instance, the US FDA acknowledged the important influence of AI and ML in medicine development in September 2021. This year, there were over 100 medication and biologic submissions with AI/ML components. Various stages of drug development, such as drug discovery, clinical research, safety surveillance, and manufacturing, all make use of AI and ML.

Threat:

Regulatory obstacles

Drug device combination products must adhere to complicated regulatory standards. It can take a lot of time and money to obtain regulatory licenses and ensure compliance with different regulatory organizations, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). However, manufacturers may have difficulties when it comes to product development, clinical studies, and market access due to strict restrictions and changing standards.

COVID-19 Impact:

The disease has expanded to over 100 nations since the COVID-19 viral epidemic in December 2019, and on January 30, 2020, the World Health Organization proclaimed it a public health emergency. However, the global market for medicine-device combination products has been significantly impacted by the COVID-19 epidemic. The market is shaped by rising demand for respiratory devices and innovations in drug-device combinations. However, issues with resource prioritization, manufacturing, and supply chain interruptions have emerged. The pandemic has stimulated industry innovation and cooperation, but the long-term effects are still being witnessed.

The transdermal patches segment is expected to be the largest during the forecast period

The segment for transdermal patches is anticipated to be the largest over the course of the projection period due to the rising demand for drug self-administration in conditions where diseases demand long-term therapy. For instance, a patient with diabetes requires frequent intravenous administration of insulin. Additionally, the need for alternative drug delivery methods is growing due to the pain and increased risk of infection associated with the frequent use of needles to deliver insulin.

The cancer treatment segment is expected to have the highest CAGR during the forecast period

Cancer Treatment segment is expected to have the highest CAGR during the forecast period. By integrating pharmacological substances and medical devices to enhance treatment outcomes, these products offer a distinctive method of cancer therapy. They make it possible to use implantable medication delivery devices, localized radiation therapy, and targeted drug delivery. Additionally, these medications offer synergistic effects and individualized treatment options by combining various therapeutic methods, including chemotherapy, immunotherapy, and targeted therapy.

Region with largest share:

Due to the region's vast population, rising frequency of chronic diseases like cancer, and rising healthcare costs, the Asia-Pacific region is anticipated to hold the largest share of the market during the projected period. Moreover, the regional market is growing as a result of increasing physician awareness of the benefits of these products, which include low dosage requirements, timed medication release, direct device-centered infection mitigation using anti-infective medication in combination, and reduced systemic exposure.

Region with highest CAGR:

Owing to the adoption of drug-device combination products along with the region's well-established healthcare infrastructure, North America is predicted to have profitable growth over the course of the projection period. Additionally, since many vaccines and other treatments are generated by these industries, there is likely to be a growth in demand for drug-device combination products as corporations invest additional funds in product research and development.

Key players in the market:

Some of the key players in Drug Device Combination Products Market include: Abbott Laboratories, Allergan plc, Boston Scientific Corporation, C.R. Bard, Medtronic Plc, Mylan N.V., Novartis AG, Stryker Corporation, Teleflex Incorporated, Terumo Corporation and W. L. Gore & Associates, Inc.

Key Developments:

In August 2022, Terumo Corporation launched G-Lasta Subcutaneous Injection 3.6 mg BodyPod", a drug-device combination product co-developed with Kyowa Kirin Co., Ltd. The product received approval from Japan's Ministry of Health, Labour, and Welfare (MHLW).

In June 2022, Novartis acquired Kedalion Therapeutics and its AcuStream technology that facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. The acquisition enhances the Novartis ophthalmics portfolio, advancing efforts to investigate transformative ophthalmic methods to address unmet patient needs in front-of-eye conditions.

Products Covered:

  • Infusion Pumps
  • Orthopedic Combination Products
  • Transdermal Patches
  • Photodynamic Therapy Devices
  • Drug Eluting Stents
  • Wound Care Products
  • Antimicrobial Catheters
  • Other Products

Applications Covered:

  • Diabetes
  • Cancer Treatment
  • Respiratory Problems
  • Other Applications

End Users Covered:

  • Home Care Settings
  • Ambulatory Surgery Centers
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Drug Device Combination Products Market, By Product

  • 5.1 Introduction
  • 5.2 Infusion Pumps
    • 5.2.1 Insulin
    • 5.2.2 Implantable
    • 5.2.3 Syringe
    • 5.2.4 Ambulatory
  • 5.3 Orthopedic Combination Products
    • 5.3.1 Antibiotic Bone Cement
    • 5.3.2 Bone Graft Implants
  • 5.4 Transdermal Patches
  • 5.5 Photodynamic Therapy Devices
  • 5.6 Drug Eluting Stents
  • 5.7 Wound Care Products
  • 5.8 Antimicrobial Catheters
    • 5.8.1 Cardiovascular
    • 5.8.2 Urological
  • 5.9 Other Products

6 Global Drug Device Combination Products Market, By Application

  • 6.1 Introduction
  • 6.2 Diabetes
  • 6.3 Cancer Treatment
  • 6.4 Respiratory Problems
  • 6.5 Other Applications

7 Global Drug Device Combination Products Market, By End User

  • 7.1 Introduction
  • 7.2 Home Care Settings
  • 7.3 Ambulatory Surgery Centers
  • 7.4 Hospitals & Clinics
  • 7.5 Other End Users

8 Global Drug Device Combination Products Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Laboratories
  • 10.2 Allergan plc
  • 10.3 Boston Scientific Corporation
  • 10.4 C.R. Bard
  • 10.5 Medtronic Plc
  • 10.6 Mylan N.V.
  • 10.7 Novartis AG
  • 10.8 Stryker Corporation
  • 10.9 Teleflex Incorporated
  • 10.10 Terumo Corporation
  • 10.11 W. L. Gore & Associates, Inc.

List of Tables

  • Table 1 Global Drug Device Combination Products Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Drug Device Combination Products Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Drug Device Combination Products Market Outlook, By Infusion Pumps (2021-2030) ($MN)
  • Table 4 Global Drug Device Combination Products Market Outlook, By Insulin (2021-2030) ($MN)
  • Table 5 Global Drug Device Combination Products Market Outlook, By Implantable (2021-2030) ($MN)
  • Table 6 Global Drug Device Combination Products Market Outlook, By Syringe (2021-2030) ($MN)
  • Table 7 Global Drug Device Combination Products Market Outlook, By Ambulatory (2021-2030) ($MN)
  • Table 8 Global Drug Device Combination Products Market Outlook, By Orthopedic Combination Products (2021-2030) ($MN)
  • Table 9 Global Drug Device Combination Products Market Outlook, By Antibiotic Bone Cement (2021-2030) ($MN)
  • Table 10 Global Drug Device Combination Products Market Outlook, By Bone Graft Implants (2021-2030) ($MN)
  • Table 11 Global Drug Device Combination Products Market Outlook, By Transdermal Patches (2021-2030) ($MN)
  • Table 12 Global Drug Device Combination Products Market Outlook, By Photodynamic Therapy Devices (2021-2030) ($MN)
  • Table 13 Global Drug Device Combination Products Market Outlook, By Drug Eluting Stents (2021-2030) ($MN)
  • Table 14 Global Drug Device Combination Products Market Outlook, By Wound Care Products (2021-2030) ($MN)
  • Table 15 Global Drug Device Combination Products Market Outlook, By Antimicrobial Catheters (2021-2030) ($MN)
  • Table 16 Global Drug Device Combination Products Market Outlook, By Cardiovascular (2021-2030) ($MN)
  • Table 17 Global Drug Device Combination Products Market Outlook, By Urological (2021-2030) ($MN)
  • Table 18 Global Drug Device Combination Products Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 19 Global Drug Device Combination Products Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 Global Drug Device Combination Products Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 21 Global Drug Device Combination Products Market Outlook, By Cancer Treatment (2021-2030) ($MN)
  • Table 22 Global Drug Device Combination Products Market Outlook, By Respiratory Problems (2021-2030) ($MN)
  • Table 23 Global Drug Device Combination Products Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 24 Global Drug Device Combination Products Market Outlook, By End User (2021-2030) ($MN)
  • Table 25 Global Drug Device Combination Products Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 26 Global Drug Device Combination Products Market Outlook, By Ambulatory Surgery Centers (2021-2030) ($MN)
  • Table 27 Global Drug Device Combination Products Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 28 Global Drug Device Combination Products Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.